Literature DB >> 7635769

The adverse effect of treatment prolongation in cervical carcinoma.

D G Petereit1, J N Sarkaria, R Chappell, J F Fowler, T J Hartmann, T J Kinsella, J A Stitt, B R Thomadsen, D A Buchler.   

Abstract

PURPOSE: Proliferation of surviving tumor clonogens during a course of protracted radiation therapy may be a cause of local failure in cervical carcinoma. The effect of total treatment time was analyzed retrospectively in relation to pelvic control and overall survival for squamous cell carcinomas of the uterine cervix. METHODS AND MATERIALS: Two hundred and nine patients (Stage IB-IIIB) treated with a combination of external beam and low dose rate intracavitary irradiation were evaluable for study. Multivariate analysis and Kaplan-Meier statistical methods were used to determine the effect of treatment time on pelvic control and survival at 5 years.
RESULTS: The median treatment duration was 55 days. For all stages combined, the 5-year survival and pelvic control rates were significantly different with treatment times < 55 days vs. > or = 55 days: 65 and 54% (p = 0.03), 87 and 72% (p = 0.006), respectively. By stage, a shorter treatment duration (i.e., < 55 days vs. > or = 55 days) was significant for 5-year overall survival and pelvic control for Stages IB/IIA and III, but not for Stage IIB: Stage IB/IIA (81 and 67%, 96 and 84%), Stage III disease (52 and 42%, 76 and 55%) and Stage IIB (43 and 50%, 74 and 80%, respectively). Survival decreased 0.6%/day and pelvic control decreased 0.7%/day for each additional day of treatment beyond 55 days for all stages of disease. Additionally, significant late complications were not influenced by treatment time.
CONCLUSION: These results suggest that prolongation of treatment time is associated with decreased local control and survival in patients with cervical carcinoma. This is consistent with emerging data from other institutions. Therapeutic implications include avoidance of unnecessary treatment breaks, the design of fractionation schemes that decrease treatment duration, and possibly the use of tumor cytostatic drugs during conventional radiation.

Entities:  

Mesh:

Year:  1995        PMID: 7635769     DOI: 10.1016/0360-3016(94)00635-X

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  63 in total

1.  Personalized medicine: challenge and promise.

Authors:  Judith Salmon Kaur; Daniel G Petereit
Journal:  J Cancer Educ       Date:  2012-04       Impact factor: 2.037

2.  Radical radiotherapy for locally advanced cancer of uterine cervix.

Authors:  Jeung Eun Lee; Seung Jae Huh; Won Park; Do Hoon Lim; Yong Chan Ahn; Chang Soo Park; Byoung Gie Kim; Duk Soo Bae; Je Ho Lee; Chong Taik Park; Tae Jin Kim; Kyung Taek Lim; Hwan Wook Chung; Ki Heon Lee; Jae Uk Shim
Journal:  Cancer Res Treat       Date:  2004-08-31       Impact factor: 4.679

Review 3.  Chemoradiotherapy for cervical cancer in 2010.

Authors:  Ann H Klopp; Patricia J Eifel
Journal:  Curr Oncol Rep       Date:  2011-02       Impact factor: 5.075

Review 4.  21 years of biologically effective dose.

Authors:  J F Fowler
Journal:  Br J Radiol       Date:  2010-07       Impact factor: 3.039

5.  Compliance to the prescribed overall treatment time (OTT) of curative radiotherapy in normal clinical practice and impact on treatment duration of counteracting short interruptions by treating patients on Saturdays.

Authors:  M Maciá I Garau; J Solé Monné; M J Cambra Serés; C Monfà Binefa; M Peraire Llopis
Journal:  Clin Transl Oncol       Date:  2009-05       Impact factor: 3.405

6.  Pure accelerated radiation versus concomitant chemoradiation in selected cases of locally advanced carcinoma cervix: a prospective study.

Authors:  Chhaya Roy; Krishnangshu Bhanja Choudhury; Madhumay Pal; Kakali Chowdhury; Ansuman Ghosh
Journal:  J Obstet Gynaecol India       Date:  2012-09-27

7.  Which clinical/pathologic factors matter in the era of chemoradiation as treatment for locally advanced cervical carcinoma? Analysis of two Gynecologic Oncology Group (GOG) trials.

Authors:  Bradley J Monk; Chunqiao Tian; Peter G Rose; Rachelle Lanciano
Journal:  Gynecol Oncol       Date:  2007-02-02       Impact factor: 5.482

Review 8.  Radiobiological considerations in combining doses from external beam radiotherapy and brachytherapy for cervical cancer.

Authors:  Ana M Tornero-López; Damián Guirado
Journal:  Rep Pract Oncol Radiother       Date:  2018-07-02

9.  Simultaneous integrated boost (SIB) of the parametrium and cervix in radiotherapy for uterine cervical carcinoma: a dosimetric study using a new alternative approach.

Authors:  Jen-Yu Cheng; Eng-Yen Huang; Shun-Neng Hsu; Chong-Jong Wang
Journal:  Br J Radiol       Date:  2016-10-06       Impact factor: 3.039

10.  A preliminary results of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer.

Authors:  Young Seok Kim; Seong Soo Shin; Eun Kyung Choi; Jong Hoon Kim; Seung Do Ahn; Sang-wook Lee; Heon-Jin Park; Young-Tak Kim; Jung-Eun Mok; Joo-Hyun Nam
Journal:  Cancer Res Treat       Date:  2005-02-28       Impact factor: 4.679

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.